

## **PRESS RELEASE**

### **Opterion successfully secures EUR 8.4m Bridge Financing Round**

- Opterion Health AG has secured commitments to raise EUR 8.4m to fund its final preclinical activities to create a new standard in Peritoneal Dialysis (PD) and prepare for Phase I
- The capital round funded by a small group of professional private and institutional investors from Switzerland and Germany, was oversubscribed by over 40%
- The company is also relocating its offices to Muttenz (BL), becoming part of the life science ecosystem of the Basel area

**Sarnen, Switzerland, 19 January 2021 – Opterion Health AG, a preclinical Swiss life science company, developing the first novel solution for peritoneal dialysis (PD) in the last two decades, today announced the successful agreement of a EUR 8.4m Bridge Financing Round. This amount was exclusively raised from a limited number of professional private and institutional investors based in Switzerland and Germany. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I.**

Opterion was founded in 2012 by scientist Guido Grentzmann. In 2015, a small number of renowned life science investors joined Opterion and meanwhile the team consists of experienced scientists and life science entrepreneurs supported by leading nephrologists in Switzerland and Europe.

The company is developing a novel peritoneal dialysis (PD) solution, aiming to revolutionize the dialysis market. Animal studies have shown the superiority of the Opterion PD solution over the “gold standard” of the current market leader.

Guido Grentzmann, the founder and CEO/CSO of Opterion comments: “The PD market has not seen any significant innovation for over two decades. Hence, there is a high unmet medical need for a novel solution that not only offers better therapy outcomes, but also has the potential for reduced side effects, improved quality of life and higher survival rates of dialysis patients. Over 45% of dialysis patients suffer from diabetes, and an increasing number of patients no longer want to visit a clinic or a hospital for their therapy. This is especially true in times of pandemic, as we are currently experiencing. Therefore, our glucose-free PD solution is a much-needed innovation not only for the very large number of diabetic dialysis patients, but also for dialysis patients who want to improve their quality of life by having their therapy at home.”

Andreas Schmidt, CFO of Opterion adds: “Thanks to the very successful completion of our financing round – which was oversubscribed by more than 40% – Opterion is now in the position of being very comfortably financed for the next two years. This gives us the opportunity to execute our scientific as well as manufacturing plans and prepare for Phase I with full speed.”

Further to the successful closing of its Bridge Financing Round, Opterion also announced that it will relocate its offices to MuttENZ (BL). That way, it will become part of the life science ecosystem in the Basel area.

**For more information, please contact:**

Beatrix Benz at [media@opterion.com](mailto:media@opterion.com) or +41 79 256 77 73

**About Opterion Health**

Opterion Health AG is a preclinical Swiss life science company headquartered in Sarnen, Switzerland. It was created by Guido Grentzmann and other renowned scientists and nephrologists. The company is focused to bring innovation to dialysis care and foster home dialysis to improve quality of life for patients as well as their loved ones and strives to increase the survival rates of people who suffer from end-stage renal disease (ESRD). [Opterion Health AG](#)